Moleculin Biotech, Inc. (MBRX)
7.90
-0.82
(-9.40%)
USD |
NASDAQ |
Oct 30, 16:00
8.10
+0.20
(+2.53%)
After-Hours: 20:00
Moleculin Biotech EPS Diluted (Quarterly) : -28.04 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -28.04 |
| March 31, 2026 | -70.85 |
| December 31, 2025 | 96.57 |
| September 30, 2025 | -340.43 |
| June 30, 2025 | -573.50 |
| March 31, 2025 | -315.93 |
| December 31, 2024 | -974.29 |
| September 30, 2024 | -945.54 |
| June 30, 2024 | -849.11 |
| March 31, 2024 | -1007.64 |
| December 31, 2023 | -2562.97 |
| September 30, 2023 | -1411.20 |
| June 30, 2023 | -1509.67 |
| March 31, 2023 | -2064.75 |
| December 31, 2022 | -1773.60 |
| September 30, 2022 | -2255.92 |
| June 30, 2022 | -1778.25 |
| March 31, 2022 | -1802.17 |
| December 31, 2021 | -741.38 |
| September 30, 2021 | -1149.37 |
| June 30, 2021 | -1118.77 |
| March 31, 2021 | -1528.65 |
| Date | Value |
|---|---|
| December 31, 2020 | -1715.40 |
| September 30, 2020 | -2485.35 |
| June 30, 2020 | -7650.00 |
| March 31, 2020 | -1089.45 |
| December 31, 2019 | -3736.80 |
| September 30, 2019 | -4102.65 |
| June 30, 2019 | -0.0288 |
| March 31, 2019 | -6256.35 |
| December 31, 2018 | -4507.65 |
| September 30, 2018 | -3414.15 |
| June 30, 2018 | -8908.20 |
| March 31, 2018 | -3716.55 |
| December 31, 2017 | -6675.75 |
| September 30, 2017 | -6280.65 |
| June 30, 2017 | -8625.15 |
| March 31, 2017 | -1014.75 |
| December 31, 2016 | -5400.00 |
| September 30, 2016 | -5400.00 |
| June 30, 2016 | -3600.00 |
| March 31, 2016 | -2250.00 |
| December 31, 2015 | -1651.95 |
| September 30, 2015 | -707.40 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -7.635M |
| Total Expenses (Quarterly) | 7.635M |
| Enterprise Value | -4.166M |
| Earnings Yield | -4.34K% |
| Normalized Earnings Yield | -3760.45 |